Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
49
days
Oral Retinol, Alone or Combined with Medical Photoprotection, in Patients with Actinic Keratosis: A Randomized, Open-Label, Prospective, Multicentric Study
AuthorsMarco Ardigò; Martina Burlando; Elena Campione; Gianluca Nazzaro; Giulio Foggi; Francesca Colombo; Stefano Alfano; Massimo Milani; Angelo V. Marzano
Affiliations1. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; 2. Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy; 3. Dermatology Unit, IRCCS San Martino University Hospital, Genoa, Italy; 4. Dermatological Clinic, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 5. Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 6. Department of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milan, Italy; 7. Medical Department, Cantabria Labs Difa Cooper, Caronno Pertusella, Italy
82
days
Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”
AuthorsSaroja Rao; Isabella Midura; Kathyana P. Santiago Mangual; Leon I. Igel; Katherine H. Saunders; Jocelyn Carter; Jenny E. Murase; Arianne Shadi Kourosh
Affiliations1. Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, USA; 2. Wake Forest University School of Medicine, Winston-Salem, USA; 3. Department of Medicine, Yale School of Medicine, New Haven, USA; 4. Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, Comprehensive Weight Control Center, New York, USA; 5. FlyteHealth, New Canaan, USA; 6. Division of General Internal Medicine, Massachusetts General Hospital, Boston, USA; 7. Department of Dermatology, University of California, San Francisco, San Francisco, USA; 8. Department of Dermatology, Palo Alto Foundation Medical Group, Mountain View, USA; 9. Harvard Medical School, Boston, USA; 10. Harvard T.H. Chan School of Public Health, Boston, USA
68
days
Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study
AuthorsAnthony Bewley; Andreas Pinter; José Luis López Estebaranz; Jordi Galván; Víctor Sapena; Volker Koscielny
Affiliations1. Department of Dermatology, Barts Health NHS Trust and Queen Mary University, London, UK; 2. Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt Am Main, Frankfurt Am Main, Germany; 3. Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain; 4. Global Medical Affairs Department, Almirall S.A., Barcelona, Spain; 5. Global Clinical Statistics Department, Almirall S.A., Sant Feliu de Llobregat, Barcelona, Spain
105
days
Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss Among Patients in a Phase 2 Clinical Trial of Povorcitinib
AuthorsMichael DePietro; Leandro L. Santos; Zhenyi Xue; Kurt Brown; Jason A. Brant
Affiliations1. Incyte Corporation, Wilmington, USA; 2. Department of Otorhinolaryngology, University of Wisconsin, Madison, USA; 3. William S. Middleton Memorial VA Medical Center, Madison, USA
54
days
Spironolactone versus Bicalutamide for Female Pattern Hair Loss: A 24-Month Unicenter Retrospective Comparative Study of Effectiveness and Safety
AuthorsRocío Gil-Redondo; Juan Jimenez-Cauhe; Adrián Imbernon-Moya; Diego Buendía-Castaño; Patricia Burgos Blasco; Borja Díaz-Guimaraens; Miguel Domínguez-Santas; Ángela Hermosa-Gelbard; David Saceda-Corralo; Sergio Vañó-Galván
Affiliations1. Hair Disorders Unit, Grupo de Dermatología Pedro Jaén, Madrid, Spain; 2. Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain; 3. Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain; 4. Departamento de Medicina, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain; 5. Department of Dermatology, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain; 6. Department of Dermatology, Olympia Medical Center, Madrid, Spain
130
days
Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study
AuthorsYayoi Tada; Hideaki Kagitani; Shuichi Kimura; Naoto Tsujimoto; Kiyotaka Mochizuki
Affiliations1. Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan; 2. Japan Drug Development and Medical Affairs, Eli Lilly Japan KK., Kobe, Japan
72
days
Scalp Rosacea: Current Evidence
AuthorsValeria Olvera-Rodríguez; Francesca Pampaloni; Andrea Sechi; Michela Valeria Rita Starace
Affiliations1. Dermatology Department, University Hospital “Dr. José Eleuterio González”, Monterrey, Mexico; 2. Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 4. Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
209
days
Effectiveness and Safety of 40 mg Modified-Release Doxycycline for the Treatment of Hidradenitis Suppurativa: A Single-Center Retrospective Observational Study
AuthorsGemma Camiña-Conforto; Luis Puig; Eva Vilarrasa
Affiliations1. Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
99
days
AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis
AuthorsMatthias Augustin; Andreas Pinter; Silvia Sabatino; Louis P. Sanden; Pablo Chicharro; Esther Serra-Baldrich; Mahreen Ameen; Anthony Bewley; Walid Fakhouri; Inmaculada de la Torre; Julien Seneschal
Affiliations1. Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; 2. Department for Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany; 3. Eli Lilly and Company, Indianapolis, USA; 4. Hospital Universitario de la Princesa, Madrid, Madrid, Spain; 5. Department of Dermatology, Cutaneous Allergy Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; 6. Department of Dermatology, Royal Free London NHS Foundation Trust, London, UK; 7. Department of Dermatology, Barts Health NHS Trust and Queen Mary University of London, London, UK; 8. CHU de Bordeaux, Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, UMR 5164, Bordeaux, France
125
days
Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study
AuthorsFelix Lauffer; Boris Bauer; Katharina Kreutzer; Knut Schäkel; Uwe Schwichtenberg; Johannes Hockmann; Andreas Pinter; Fatima Abousamra; Melanie Huber; Stephan Weidinger
Affiliations1. Department of Dermatology and Allergy, LMU Hospital, Munich, Germany; 2. Dermatology Practice Hassberge, Haßfurt, Germany; 3. Department of Dermatology, Venereology and Allergology, University Hospital OWL, University Bielefeld, Bielefeld, Germany; 4. Department of Dermatology, Heidelberg University Hospital, Heidelberg, Germany; 5. Derma Nord Dermatology Practice, Bremen, Germany; 6. Dermatology Practice Oelde, Oelde, Germany; 7. Department of Dermatology, Venereology and Allergology, Clinical Research, University Hospital, Frankfurt Am Main, Germany; 8. AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany; 9. UFL Private University in the Principality of Liechtenstein, Triesen, Liechtenstein; 10. Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days